



Attorney Docket No.: 5698.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 10/076,575

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

Confirmation No.: 2403

For: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ Activators (As Amended)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment/Response
2. Review Articles (2)

is being deposited with the United States Postal Service as Express Mail Label No. EV 246880289 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 5, 2004

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)



Attorney Docket No. 5698.220-US
Jeppesen et al.
Serial No. 10/076,575 Filed February 8, 2002
Express Mail Label No. EV 246880289 US

8-6-04

AG/624

JF

Attorney Docket No.: 5698.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 10/076,575

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

Confirmation No.: 2403

For: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ Activators (as amended)

AMENDMENT/RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is submitted in response to the Office Action on the merits mailed May 12, 2004, having a shortened statutory period for reply set to expire August 12, 2004, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this amendment/response, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk Pharmaceuticals, Inc., for any such required fee.

The Examiner states in the Office Action Summary that claims numbered 1, 2, 7, 17, 45-47, 54 and 55 are pending in the application; claims numbered 1, 2, 7, 17, 45-47, and 55 are allowed; and claim number 54 is rejected.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application, with current amendments noted.

Claim number 54 has been amended.